Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Utomilumab · PF-5082566

Monoclonal antibody · Agonist of 4-1BB (CD137) (TNFRSF9) · developed by PFIZER

Phase 3 Most advanced trial
PFE Developer

What is Utomilumab?

Utomilumab is a human IgG2 monoclonal antibody that binds and activates 4-1BB (CD137, TNFRSF9) on CD8-positive and CD4-positive T cells and natural killer cells. This agonism enhances 4-1BB signaling and cytokine production to promote anti-tumor immune responses. It is studied in advanced malignancies, non-small cell lung cancer, ovarian cancer, urothelial cancer and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PF-5082566
Drug type
Monoclonal antibody
Targets
4-1BB (CD137) (TNFRSF9)
Mechanism
Agonist of 4-1BB (CD137) (TNFRSF9)
Pathways
4-1BB-mediated T cell and NK cell signaling, cytokine production
Therapy area
Oncology
Developer
PFIZER (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
6YY8O697VF

Conditions studied

Advanced MalignanciesNSCLCOvarian CancerSolid TumorsUrothelial Cancer

Other drugs acting on TNFRSF9

More from PFIZER

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Utomilumab

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.